Blood protein predictors of brain amyloid for enrichment in clinical trials?

Measures of neocortical amyloid burden (NAB) identify individuals who are at substantially greater risk of developing Alzheimer's disease (AD). Blood‐based biomarkers predicting NAB would have great utility for the enrichment of AD clinical trials, including large‐scale prevention trials.

[1]  A. Goate,et al.  Clearance of amyloid-beta by circulating lipoprotein receptors. , 2007, Nature medicine.

[2]  R. Faber,et al.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.

[3]  B. Långström,et al.  The use of PET in Alzheimer disease , 2010, Nature Reviews Neurology.

[4]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[5]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[6]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[7]  Jerry L. Prince,et al.  A computational neurodegenerative disease progression score: Method and results with the Alzheimer's disease neuroimaging initiative cohort , 2012, NeuroImage.

[8]  N. Sousa,et al.  Blood–brain-barriers in aging and in Alzheimer’s disease , 2013, Molecular Neurodegeneration.

[9]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[10]  P. Sachdev,et al.  Plasma Apolipoprotein Levels Are Associated with Cognitive Status and Decline in a Community Cohort of Older Individuals , 2012, PloS one.

[11]  Markus Rudin,et al.  Contrast-Enhanced Magnetic Resonance Microangiography Reveals Remodeling of the Cerebral Microvasculature in Transgenic ArcAβ Mice , 2012, The Journal of Neuroscience.

[12]  Christopher C Rowe,et al.  Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease , 2007, Journal of Nuclear Medicine.

[13]  H. Kiiveri,et al.  A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study , 2014, Molecular Psychiatry.

[14]  Simone Lista,et al.  Blood and plasma-based proteomic biomarker research in Alzheimer's disease , 2013, Progress in Neurobiology.

[15]  Magda Tsolaki,et al.  Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. , 2013, Journal of Alzheimer's disease : JAD.

[16]  Magda Tsolaki,et al.  Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden , 2012, PloS one.

[17]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[18]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[19]  Christine M. Walsh,et al.  Interleukin-6, Age, and Corpus Callosum Integrity , 2014, PloS one.

[20]  J. Haines,et al.  ApoE-4 and Age at Onset of Alzheimer's Disease , 1997, Neurology.

[21]  J. Melchor,et al.  Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. , 2007 .

[22]  G. Xu,et al.  Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment , 2007, International journal of clinical practice.

[23]  Magda Tsolaki,et al.  Plasma proteins predict conversion to dementia from prodromal disease , 2014, Alzheimer's & Dementia.

[24]  Olivier Salvado,et al.  Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. , 2012, Brain : a journal of neurology.

[25]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[26]  Harald Hampel,et al.  Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease , 2014, Neuropsychopharmacology.

[27]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[28]  J. Ryu,et al.  A leaky blood–brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain , 2008, Journal of cellular and molecular medicine.

[29]  Magda Tsolaki,et al.  Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology , 2014, Alzheimer's & Dementia.

[30]  L. Ferrucci,et al.  Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. , 2011, Journal of Alzheimer's disease : JAD.

[31]  Eileen Daly,et al.  Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer’s disease , 2008, Journal of Neurology.

[32]  Christos Davatzikos,et al.  Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment , 2012, NeuroImage.

[33]  Albert Hofman,et al.  Fibrinogen Is Associated With an Increased Risk of Alzheimer Disease and Vascular Dementia , 2005, Stroke.

[34]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[35]  Yi Zhang,et al.  Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease , 2011, PloS one.

[36]  S. Strickland,et al.  Fibrinogen and β-Amyloid Association Alters Thrombosis and Fibrinolysis: A Possible Contributing Factor to Alzheimer's Disease , 2010, Neuron.

[37]  Keith A. Johnson,et al.  Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging , 2013, Alzheimer's & Dementia.

[38]  E. Anderson.  Hudson et al. , 1977 .

[39]  J O Rinne,et al.  Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls , 2009, Neurology.

[40]  C. Rowe,et al.  The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.

[41]  J. Kornak,et al.  Amyloid Vs Fdg-pet in the Differential Diagnosis of Ad And , 2022 .

[42]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[43]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[44]  D. Hochstrasser,et al.  Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. , 2008, Analytical chemistry.

[45]  L. Thurfjell,et al.  Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease , 2009, Journal of Nuclear Medicine.

[46]  S. Strickland,et al.  Alzheimer's disease peptide β-amyloid interacts with fibrinogen and induces its oligomerization , 2010, Proceedings of the National Academy of Sciences.

[47]  C. Ballard,et al.  New and emerging treatments for Alzheimer's disease , 2012, Expert opinion on emerging drugs.

[48]  Deborah Blacker,et al.  Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. , 2012, Archives of neurology.

[49]  Cindee M. Madison,et al.  Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. , 2013, Brain : a journal of neurology.

[50]  A. Goate,et al.  Clearance of amyloid-β by circulating lipoprotein receptors , 2007, Nature Medicine.

[51]  Robert E. Kearney,et al.  Methods for combining peptide intensities to estimate relative protein abundance , 2010, Bioinform..

[52]  M. Freedman,et al.  Frontotemporal lobar degeneration , 1998, Neurology.

[53]  Muzamil Saleem,et al.  Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[54]  P. Aisen,et al.  Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease , 2013, Nature Reviews Drug Discovery.

[55]  M. Nalls,et al.  Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype , 2013, Biological Psychiatry.

[56]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[57]  P. Zürbig,et al.  Use of proteomic methods in the analysis of human body fluids in Alzheimer research , 2012, Electrophoresis.

[58]  F. Grodstein,et al.  Plasma amyloid-beta as a predictor of dementia and cognitive decline: A systematic review and meta-analysis , 2011, Alzheimer's & Dementia.

[59]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.